Skip to content

Clinical study of intraoperative superselective injection of methylene blue for imaging parathyroid glands

Clinical study of intraoperative superselective injection of methylene blue for imaging parathyroid glands

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077263
Enrollment
Unknown
Registered
2023-11-02
Start date
2020-03-01
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoparathyroidism

Interventions

Group A:Retrograde injecting methylene blue into the arteriae thyreoidea inferior, then performing unilateral thyroidectomy
Group B:Injecting Nano-Carbon into the thyroid gland, then performing unilateral thyroidectomy
Group C:Unilateral thyroid gland lobe was removed

Sponsors

The Sixth Medical Center of PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
21 Years to 77 Years

Inclusion criteria

Inclusion criteria: ?Differentiated thyroid carcinoma was identified by preoperative FNAC (fine needle puncture pathology) or intraoperative freezing pathology.?According to ATA (American Thyroid Association) standards, papillary carcinoma with a maximum nodule diameter of less than 10mm (intraoperative freezing pathology) that exists only in a unilateral gland is defined as micropapillary carcinoma, unilateral lobectomy plus isthmus resection, unilateral central lymph node dissection, total thyroidectomy for remaining differentiated cancers, and bilateral central lymph node dissection.

Exclusion criteria

Exclusion criteria: ?Age less than 15 years old or more than 78 years old; ?pregnant women; ?There are serious organic diseases that need to be completed as soon as possible; ?history of surgery in the neck area; ?consistent with the diagnosis of retrosternal thyroid; ?FNAC or intraoperative pathology considering medullary carcinoma or undifferentiated carcinoma.

Design outcomes

Primary

MeasureTime frame
Parathyroid;Blood calcium;

Secondary

MeasureTime frame
Parathyroid hormone;

Countries

China

Contacts

Public ContactXiliang Zhang

The Sixth Medical Center of PLA General Hospital

179122711@qq.com+86 139 1092 3255

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026